Pre-made Vedolizumab benchmark antibody ( Whole mAb, anti-ITGA4;ITGB7 therapeutic antibody, Anti-CD49D/IA4 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-616
Pre-made Vedolizumab benchmark antibody (Whole mAb, anti-ITGA4;ITGB7 therapeutic antibody, Anti-CD49D/IA4 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc (currently named Takeda Oncology, a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. It is marketed under the trade name Entyvio.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Vedolizumab biosimilar, Whole mAb, Anti-ITGA4;ITGB7 Antibody: Anti-CD49D/IA4 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology|
|Conditions Approved||Crohn's disease;Ulcerative colitis|
|Conditions Active||Graft-versus-host disease;Coeliac disease|
|Conditions Discontinued||Malignant melanoma|